Melanoma Molecular Maps Projects

Padova

Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;


  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);


  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.


Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.



LATEST NEWS
The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.




REFERENCE(S):

"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Gacević M, Jović M, Zolotarevski L, Stanojević I, Novaković M, Miller K, Šuljagić V, Mijušković Ž, Vojvodić D
Vojnosanit Pregl. 2016 May;73(5):449-57.
PMID: 27430109 [PubMed - in process]

Neuropeptide Y expression in primary cutaneous melanoma.
Pérez Tato B, Juarranz Á, Nájera L, Mihm MC, Fernández P, Gilaberte Y, González S
J Eur Acad Dermatol Venereol. 2016 Jul 18;():.
PMID: 27427400 [PubMed - as supplied by publisher]

[The role of reflectance confocal microscopy in the diagnosis of cutaneous melanoma metastasis].
Perrot JL, Labeille B, Habougit C, Douchet C, Tognetti L, Cambazard F, Cinotti E, groupe d’imagerie cutanée non invasive (ICNI) de la Société française de dermatologie
Ann Dermatol Venereol. 2016 Jul 11;():.
PMID: 27418007 [PubMed - as supplied by publisher]

Could a specific dietary intake be a risk factor for cutaneous melanoma?
Hohmann CB, Bonamigo RR, Segatto MM, Costa MM, Mastroeni S, Fortes C
Cutis. 2016 Jun;97(6):421-5.
PMID: 27416086 [PubMed - in process]

IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.
Saul L, Ilieva KM, Bax HJ, Karagiannis P, Correa I, Rodriguez-Hernandez I, Josephs DH, Tosi I, Egbuniwe IU, Lombardi S, Crescioli S, Hobbs C, Villanova F, Cheung A, Geh JL, Healy C, Harries M, Sanz-Moreno V, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN
Sci Rep. 2016 Jul 14;6():29736.
PMID: 27411958 [PubMed - in process]


NCBI's Disclaimer and Copyright notice